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Abstract. Background: Monocytes/macrophages may be
affected by tumour cells via cell-to-cell contact, soluble
factors and by tumour-derived microvesicles (TMV). Previous
observations indicate that TMV interact with monocytes and
alter their immunophenotype and activity. This study was
designed to determine interactions of TMV with
subpopulations (CD14++CD16– and CD14+CD16++) of
human monocytes. Methods: Engulfment of TMV by subsets
of monocytes was analysed by flow cytometry. Moreover
cytokine release and production of reactive oxygen
intermediates (ROI) and reactive nitrogen intermediates
(RNI) by CD14++CD16– and CD14+CD16++ cells after
TMV stimulation was determined. Results: It was found that
TMV are engulfed more efficiently by CD14++CD16– than
CD14+CD16++ cells. TMV-activated CD14++CD16– cells
produce more ROI and interleukin -10 (IL-10) than
CD14++CD16+. CD14+CD16++ cells following TMV
stimulation showed an increased release of tumour necrosis
factor alpha, IL-12p40 and RNI. Conclusion: TMV
significantly modulate biological activity of monocyte subsets
with a pattern similar to tumour cells. Therefore, TMV mimic
the activating effect of tumour cells on monocytes as
assessed by release of cytokines, ROI and RNI.
Human monocytes (MO) are heterogeneous population of cells
that differ in morphology, phenotype and function (1-5). In
particular, the different expression of CD14 (the part of the
receptor for lipopolysaccharide) and of CD16 (Fcγ receptor III)
was initially used to define two major subsets in peripheral
blood, the so called ‘classical’ CD14++ CD16– MO, typically
representing up to 90-95% of all MO, and ‘non-classical’
CD14+CD16++ comprising the remaining fraction of MO (6,
7). The CD14+CD16++ subset is the main producer of tumour
necrosis factor (TNF) (8) and is expanded during infection and
inflammation, in particular in sepsis (9-11). This subset is also
formed during in vitro cytokine-induced differentiation from
CD14++CD16– (12), supporting the earlier suggestion that it
may represent a transitory stage of its differentiation (4).
CD14+CD16++ cells constitute the main subpopulation of
blood monocytes involved in antitumour response as judged by
an enhanced cytotoxicity and production of proinflammatory
cytokines (TNF, IL-12) and reactive nitrogen intermediates
(RNI) (13). It has been previously suggested that MO and
tumour-infiltrating macrophages (TIM) may be affected by
tumour cells not only by a direct cell-to-cell contact and
soluble factors but also by tumour-derived microvesicles
(TMV) (14-16). TMV are small membrane fragments that are
released spontaneously by tumour cells during proliferation,
migration, activation and apoptosis (16-19). TMV are
heterogeneous in shape and size (10 nm - 1 μm) (16, 20). TMV
show the expression of several tumour cell determinants such
as CD44, CD95L, CD147 (extracellular matrix metallo-
proteinase inducer, EMMPRIN), CD66 (carcinoembryonal
antigen CEA), chemokine receptors (CCR6, CX3CR1) and
tumour-associated antigens (Her2/neu) (17, 20-27).
Using an in vitro model, MO interactions with TMV
released by three tumour cell lines (pancreatic, lung and
colorectal carcinomas) have previously been described (16).
TMV, as well as tumour cells, are able to activate MO as
judged by production of cytokines (TNF, IL-10, IL-12), ROI
(28) and chemokines (unpublished). With this in mind, this
study compared interactions of CD14++CD16– and
CD14+CD16++ MO subsets with TMV in terms of cytokines,
ROI and RNI production during in vitro culture. 
Materials and Methods
TMV isolation. TMV were obtained as previously described (16).
Briefly, human cell lines: HPC-4 (pancreatic adenocarcinoma,
TMVHPC) and DeTa (colorectal adenocarcinoma, TMVDeTa) were
cultured in RPMI 1640 medium (Sigma, St. Louis, MO, USA) with
5% foetal bovine serum (FBS; PAA Laboratories, Pasching, Germany).
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Supernatants from well grown cell cultures were collected and spun
down at 2000×g for 20 min to remove cell debris. Then supernatants
were again centrifuged (RC28S, Sorvall, Newton, CT, USA) at
50,000×g for 1 hour at 4˚C. Pellets were washed several times to
remove FBS and finally resuspended in serum-free RPMI-1640
medium. Quantification of TMV proteins was evaluated by the
Bradford method (BioRad, Hercules, CA, USA). TMV were tested for
endotoxin contamination by the Limmulus test according to
manufacturer’s instruction (Charles River Laboratories, Inc.,
Wilmington, MA, USA) and stored at –20˚C. TMVHPC were used in
all experiments, where TMVDeTa only for RNI testing.
Isolation of MO subpopulation. Human peripheral blood
mononuclear cells were isolated from EDTA-blood of healthy donors
by the standard Ficoll/Isopaque (Pharmacia, Uppsala, Sweden)
density gradient centrifugation. MO were separated from
mononuclear cells by counter-flow centrifugal elutriation with the
JE-6.B elutriation system equipped with a 5 ml Sanderson separation
chamber (Beckman, Palo Alto, CA, USA), as previously described
(29). MO were suspended in RPMI-1640 culture medium
supplemented with L-glutamine and gentamycin (25 μg/ml) (Sigma).
The CD14++CD16– and CD14+CD16++ monocyte subpopulations
were isolated from elutriated MO by cell sorting with the use of a
FACS Aria cell sorter (BD Biosciences Immunocytometry Systems,
San Jose, CA, USA). MO were labelled by using CD14 APC
(allophycocyanin) and CD16 PE-Cy7 (phycoerytrin-cyanine 7)
conjugated monoclonal antibodies (mAbs; BD Biosciences
Pharmingen, San Diego, CA, USA). To exclude natural killer (NK)
cells contamination surface expression of HLA-DR antigens was
checked for by using peridinin chlorophyll protein complex (PerCP)
conjugated mAb (BD Biosciences). Sorted cells (CD14++CD16– and
CD14+CD16++) were collected into tubes precoated with FBS to
avoid plastic charging and cell attachment to the wall. The purity of
sorted cells was checked by flow cytometry and exceeded 95%. 
Transfer of TMV to MO subpopulations. TMV were incubated for 5
min with red PKH26 dye (Sigma) according to the manufacturer’s
instructions. Then TMV were washed with 1% bovine serum albumin
and several times in serum-free RPMI-1640 medium. Sorted cells
CD14++CD16– and CD14+CD16++ (1×106 cells/ml) were incubated
with PKH26-labelled TMV (30 μg/ml) for 18 hours at 37˚C in the
medium supplemented with 5% FBS. Engulfment of PKH26-labelled
TMV by MO subsets was determined by flow cytometry
(FACSCanto, BD Bioscience). Red fluorescence intensity and the
percentage of positive cells were analysed after quenching
extracellular fluorescence with crystal violet as described before (16). 
Determination of cytokine secretion. Control MO (elutriated but not
sorted) and sorted CD14++CD16– and CD14+CD16++ cells were
cultured for 18 hours in 96 well microplates (1×105 cells/well) at
37˚C, 5% CO2 in a humidified atmosphere in the presence of TMV
(30 μg/ml). Supernatants were collected and the concentrations of
TNF, IL-10 and IL-12p40 were measured by ELISA. The following
matched mAbs pairs for ELISA were used (PharMingen, San Diego,
CA, USA): for TNF Mab1 (capture) and Mab11 (detection), for IL-
10, JES3-9d7 (capture) and JES-12G8 (detection) and for IL-12p40
C8.3 (capture) and C8.6 (detection). Recombinant human cytokines
(all from PharMingen) were used as standards. Tests were
performed according to the manufacturer’s protocol and results were
determined with ELISA reader (BioTek Instruments, Vinooski, VT,
USA) at 492 vs. 630 nm wavelength. Detection level for TNF was
20 pg/ml, and 10 pg/ml for IL-10, IL-12p40. The tested cytokines
were not detected in TMV. 
Determination of ROI production by flow cytometry. The
intracellular production of O2- and H2O2 was measured by flow
cytometry using oxidation-sensitive fluorescent probes
hydroethidine (HE, Sigma) and dihydrorhodamine 123 (DHR123),
respectively (30). MO and sorted subsets of MO were incubated at
37˚C for 2 hours alone or with TMV (30 μg/ml) in the presence of
10 μM HE and 40 μM DHR123 (both from Sigma). Analysis was
performed with FACSCanto cytometer (BD Biosciences).
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Figure 1. Transfer of PKH26-labelled TMVHPC to MO subsets. Flow
cytometry of CD14++CD16– (right panel) and CD14+CD16++ (left
panel) cells exposed to PKH26-labelled-TMVHPC for 18 hours followed
by quenching of extracellular fluorescence with crystal violet. One
representative experiment of four performed is presented. 
Figure 2. The effect of TMV on cytokine release by MO subpopulations.
MO subsets were incubated for 18 hours with TMVHPC (30 μg/ml).
Cytokine levels in the culture supernatants were determined by ELISA.
Cytokines were not detected in the culture supernatant of control
monocytes (medium) or TMV alone. Data represent the mean±SD of six
independent experiments. *p<0.05. 
Nitric oxide secretion. MO and their subpopulations (2×105
cells/well) were cultured with TMVDeTa (30 μg/ml) for 18 hours in
the presence of fluorescent dye diaminofluorescein-2 (DAF-2).
TMVDeTa were chosen because only DeTa tumor cells induce NO
in our hands (31). TMVHPC were used as a negative control. NO
production was analysed by flow cytometry.
Statistical analysis. Statistical analysis was performed by
nonparametric Mann-Whitney test. Differences were considered
significant at p<0,05.
Results
Determination of TMV engulfment. It has been previously
shown that TMV can adhere to MO surface and this
adherence is followed by the engulfment of TMV. The
present study investigated whether engulfment of TMV was
similar for both subsets (CD14++CD16– and CD14+CD16++)
of MO. The MO subsets were incubated with PKH26-
labelled TMV for 18 hours. Data showed that after an
overnight incubation TMV were located intracellulary,
mainly in CD14++CD16– cells. Only a small percentage of
CD14+CD16++ cells showed red fluorescence inside (Figure
1). No differences in TMV attachment to monocyte subsets
were observed (data not shown).
Cytokine secretion. Previous studies have shown that TMV,
as well as tumour cells, stimulate production of TNF, IL-10,
IL-12 by MO (28, 32). The experiments in this study were
undertaken to determine cytokine secretion by the
subpopulations of MO stimulated with TMV. Figure 2 shows
that the whole population of MO and CD14++CD16– cells
after stimulation with TMV secreted comparable amounts of
TNF, IL-10 and IL-12p40. Secretion of TNF and IL-12p40
by CD14+CD16++ cells was significantly higher in
comparison to initial MO or CD14++CD16– cells. In
contrast, secretion of IL-10 by CD14+CD16++ cells was
significantly lower than by MO and CD14++CD16–. Neither
TMV alone or control monocytes released measurable
amounts of tested cytokines (data not shown). 
Production of ROI. Tumour cells and TMV are able to
induce ROI production by MO (28, 32). As tumour cells
induce ROI production mainly by CD14++CD16– cells (13),
this study examined whether this subpopulation is the main
producer of ROI after TMV stimulation. Initial MO and their
subsets were stimulated for 2 hours with TMV and
production of H2O2 and O2– was measured by flow
cytometry. Figure 3 shows that ROI production by MO and
CD14++CD16– cells was comparable and significantly higher
than by CD14+CD16++ cells.
Production of RNI. Production of RNI (NO) was assessed
by intracellular staining with DAF-2 in MO and their
subsets after 18 h stimulation with TMVDeTa. A
significantly higher percentage of DAF-2 positive cells was
found among CD14+CD16++ cells in comparison to
CD14++CD16– cells (Figure 4), suggesting that the former
are main producers of NO.
Discussion
The present study showed that subpopulations
(CD14++CD16–, CD14+CD16++) of MO interact with TMV
in different manners. First, there were differences in TMV
engulfment by MO subsets, as CD14++CD16– internalized
more TMV than CD14+CD16++ cells. Second, CD14+CD16++
cells were the main subpopulation of MO, which, when
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Figure 3. The effect of TMV on intracellular production of O2- and
H2O2 by MO subpopulations. The level of O2- and H2O2 production was
determined by flow cytometry using oxidation-sensitive probes HE and
DHR123, respectively. MO subsets were incubated alone or with TMV
(30 μg/ml) in the presence of HE or DHR123 for 2 hours. Data
represent mean±SD of five independent experiments; *p<0.05.
Figure 4. The effect of TMV on production of NO by MO subpopulations.
The level of NO was determined by flow cytometry using DAF-2 probe.
MO subsets were incubated alone or with TMV (30 μg/ml) in the
presence of DAF-2 for 18 h. Data represent mean±SD of six independent
experiments; *p<0.05. 
stimulated with TMV, produce pro-inflammatory cytokines
(TNF, IL-12) and RNI. In contrast, CD14++CD16– cells
exposed to TMV released more IL-10 and ROI, but less TNF
and IL-12p40.
MO and macrophages play a dual role in the host’s
response to the growing tumour as they both enhance or
inhibit proliferation of malignant cells (14). The final
outcome of MO effect may depend on the production of
various mediators including cytokines, growth factors,
proangiogenic and angiostatic factors, etc. On the other hand,
tumour cells may affect MO by direct cell-to-cell contact, via
soluble factors or by TMV (14, 28, 33, 34). Contact of MO
with TMV results in cytokine (TNF, IL-10, IL-12) and ROI
production with the pattern similar to tumour cell stimulation
(28, 32, 35).
Since the response of MO subsets to tumour cells is
different, it was investigated whether MO subsets interact with
TMV in a pattern similar to tumour cells. CD14++CD16– cells
are characterised by a high phagocytic activity and generation
of ROI (13, 36). This is in keeping with the current
observations that after TMV stimulation CD14++CD16– cells
release less TNF and IL-12 and show enhanced ROI production
(H2O2 and O2-) in comparison to the CD14+CD16++ subset.
These data were supported by analysis of TMV engulfment by
subpopulation of MO. Approximately 60% of CD14++CD16–
showed PKH26-labelled TMV red fluorescence not quenched
by crystal violet, which indicates intracellular localization of
TMV. Strong engulfment of TMV by CD14++CD16– cells,
known as precursors of professional phagocytes, may suggest
the role of phagocytosis/receptor mechanism in TMV
internalization. On the other hand, CD14+CD16++, which are
rather poor phagocytes, expressed only 10% of cells with
intracellular red fluorescence after incubation with PKH26
labelled-TMV. CD14+CD16++ cells represent only 5-10% of
total human MO (37), and showed an increased release of TNF,
IL-12 and RNI after lipopolysaccharide or tumour cell
stimulation, in comparison to CD14++CD16– cells (4, 7, 13,
36). Also stimulation with TMV induces significantly higher
secretion of proinflammatory cytokines (TNF, IL-12p40) by
CD14+CD16++ than CD14++CD16– cells. This is in
concordance with previous data suggesting that CD14+CD16++
cells are the main subpopulation of MO involved in antitumour
response as judged by cytotoxicity and production of
proinflamatory cytokines (13). In addition, it has previously
been shown that HLA-DR is involved in signalling for TNF
production by monocytes stimulated with tumour cells (38).
This may be relevant also in the present study, as an increased
expression of HLA-DR is observed in the CD14+CD16++
subpopulation. TMV, which are present in culture supernatant
may possibly induce NO production in monocytes via CD29
or CD44 molecules, which are expressed on MO. The current
results clearly showed that TMV may mimic tumour cell effect
on MO subsets. The precise mechanism of interactions of
TMV with MO subset is not clear, but ligand-receptor binding
should be taken into consideration as TMV may carry several
antigens presented on tumour cells (16, 20). This hypothesis
was partially proven, as blocking CD44 molecules on MO was
sufficient to diminish production of TNF after TMV
stimulation (28). 
In summary, the exact activity of human MO in
malignancy remains not fully understood, but the data
presented here increase the knowledge about MO–tumour
cell interactions, highlighting the role of TMV in monocyte-
mediated antitumour response. 
Acknowledgements
This study was supported by the Jagiellonian University Medical
College (grant no. K/ZDS/001481). The authors thank Ms B. Hajto
and I. Ruggiero for skilful technical assistance. 
References
1 Norris DA, Morris RM, Sanderson RJ and Kohler PF: Isolation of
functional subsets of human peripheral blood monocytes. J Im-
munol 123: 166-172, 1979.
2 Zembala M, Uracz W, Ruggiero I, Mytar B and Pryjma J:
Isolation and functional characteristic of FcR+ and FcR– human
monocyte subsets. J Immunol 133: 1293-1299, 1984. 
3 Wang SY, Mak KL, Chen LY, Chou MP and Ho CK:
Heterogeneity of human blood monocytes: two subpopulations
with different sizes, phenotypes and functions. Immunol 77:
298-303, 1992.
4 Ziegler-Heitbrock HW: Heterogeneity of human blood
monocytes: the CD14+/CD16+ subpopulation. Immunol Today
17: 424-428, 1996.
5 Grage-Griebenow E, Flad H-D and Ernst M: Heterogeneity of
human peripheral blood monocyte subsets. J Leukoc Biol 69: 11-
20, 2001.
6 Passlick B, Flieger D and Ziegler-Heitbrock HW: Identification
and characterization of novel monocyte subpopulation in human
peripheral blood. Blood 74: 2527-2534,1989.
7 Ziegler-Heitbrock HW, Fingerle G, Strobel M, Schraut W, Stelter
F, Schutt C, Passlick B and Pforte A: The novel subset of
CD14+/CD16+ blood monocytes exhibits features of tissue
macrophages. Eur J Immunol 23: 2053-2058, 1993.
8 Belge KU, Dayyani F, Horelt A, Siedlar Frankenberger B, Espevik
T and Ziegler–Heitbrock L: The proinflammatory CD14+CD16+
DR++ monocytes are a major source of TNF. J Immunol 168:
3536-3542, 2002.
9 Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M and
Ziegler-Heitbrock HW: The novel subset of CD14+/CD16+ blood
monocytes is expanded in sepsis patients. Blood 82: 3170-3176,
1993.
10 Nockher WA and Scherrberich JE: Expanded CD14+CD16+
monocyte subpopulation in patients with acute and chronic infections
undergoing hemodialysis. Infect Immun 66: 2782-2790, 1998.
11 Skrzeczynska J, Kobylarz K, Hartwich Z, Zembala M and
Pryjma J: CD14+CD16+ monocytes in the course of sepsis in
neonates and small children: monitoring and functional studies.
Scan J Immunol 55: 629-638, 2002.
ANTICANCER RESEARCH 30: 3515-3520 (2010)
3518
12 Skinner NA, Maclsaac CM, Hamilton JA and Visvanathan K:
Regulation of Toll-like receptor (TLR) 2 and TLR4 on
CD14dimCD16+ monocytes in response to sepsis related
antigens. Clin Exp Immunol 141: 270-278, 2005.
13 Szaflarska A, Baj-Krzyworzeka M, Siedlar M, Weglarczyk K,
Ruggiero I, Hajto B and Zembala M: Antitumor response of
CD14+/CD16+ monocyte subpopulation. Exp Haematol 32: 748-
755, 2004.
14 Mantovani A, Sozzani S, Locati M, Allavena P and Sica A:
Macrophage polarization: tumor-associated macrophages as a
paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol 23: 549-55, 2002.
15 Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati
M: The chemokine system in diverse forms of macrophage
activation and polarization. Trends Immunol 25: 677-686, 2004.
16 Baj-Krzyworzeka M, Szatanek R, Węglarczyk K, Baran J,
Urbanowicz B, Branski P, Ratajczak MZ and Zembala M: Tumour-
derived microvesicles carry several surface determinants and
mRNA of tumour cells and transfer some of these determinants to
monocytes. Cancer Immol Immunother 55: 808-818, 2006. 
17 Friedl P, Maaser K, Klein CE, Niggemann B, Krohne G and
Zanker KS: Migration of highly aggressive MV3 melanoma cells
in 3-dimensional collagen lattices results in local matrix
reorganization and shedding of alpha2 and beta1 integrins and
CD44. Cancer Res 57: 2061-2070, 1997. 
18 Ginestra A, Miceli D, Dolo V, Romano FM and Vittorelli ML:
Membrane vesicles in ovarian cancer fluids: a new potential
marker. Anticancer Res 19: 3439-3445, 1999.
19 Poste G and Nicolson GL: Arrest and metastasis of blood-borne
tumor cells are modified by fusion of plasma membrane vesicles
from highly metastatic cells. Proc Natl Acad Sci USA 77: 399-
403, 1980.
20 Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R,
Zembala M, Barbasz J, Czupryna A, Szczepanik A and Zembala
M: Circulating tumour-derived microvesicles in plasma of gastric
cancer patients. Cancer Immunol Immunother 59: 841-850, 2010.
21 Dolo V, Adobati E, Canevari S, Picone MA and Vittorelli ML:
Membrane vesicles shed into the extracellular medium by human
breast carcinoma cells carry tumor-associated surface antigens.
Clin Exp Metastasis 13: 277-286, 1995.
22 Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi
MR, Nagase H, Canevari S, Pavan A and Vittorelli ML: Selective
localization of matrix metalloproteinase 9, beta1 integrins, and
human lymphocyte antigen class I molecules on membrane
vesicles shed by 8701-BC breast carcinoma cells. Cancer Res
58: 4468-4474, 1998.
23 Mayer C, Maaser K, Daryab N, Zanker KS, Brocker EB and
Friedl P: Release of cell fragments by invading melanoma cells
Eur J Cell Biol 83: 709-715, 2004. 
24 Sidhu SS, Mengistab AT, Tauscher AN, LaVail J and Basbaum
C: The microvesicle as a vehicle for EMMPRIN in tumor-
stromal interactions. Oncogene 29: 956-963, 2004. 
25 Taylor DD and Black PH: Shedding of plasma membrane
fragments. Neoplastic and developmental importance. Dev Biol
(NY 1985) 3: 33-57, 1986.
26 Taylor DD and Gercel-Taylor C: Tumour-derived exosomes and
their role in cancer-associated T-cell signaling defects. Br J
Cancer 92: 305-311, 2005.
27 Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S and
Rivoltini L: Tumour-released exosomes and their implications in
cancer immunity Cell Death Differ 15: 80-88, 2008. 
28 Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J and
Zembala M: Tumour-derived microvesicles modulate biological
activity of human monocytes. Immunol Lett 113: 76-82, 2007.
29 Baran J, Guzik K, Hryniewicz W, Ernst M, Flad H-D and Pryjma
J: Apoptosis of monocytes and prolonged survival of
granulocytes as a result of phagocytosis of bacteria. Infect
Immun 64: 4242-4246, 1996.
30 Baran J, Weglarczyk K, Mysiak M, Guzik K, Ernst M, Flad H-
D and Pryjma J: Fas (CD95)-FasL (CD95L) interactions are
responsible for monocyte apoptosis occurring as a result of
phagocytosis and killing of Staphylococcus aureus. Infect
Immun 69: 1287-1291, 2001.
31 Siedlar M, Mytar B, Krzeszowiak A, Baran J, Hyszko M,
Ruggiero I, Wieckiewicz J, Stachura J and Zembala M:
Demonstration of iNOS mRNA in human monocytes stimulated
with cancer cells in vitro. J Leukoc Biol 65: 597-604, 1999.
32 Mytar B, Siedlar M, Woloszyn M, Ruggiero I, Pryjma J and
Zembala M: Induction of reactive oxygen intermediates in
human monocytes by tumour cells and their role in spontaneous
monocyte cytotoxicity. Br J Cancer 79: 737-743, 1999.
33 Siedlar M, Marcinkiewicz J and Zembala M: MHC class I and
class II determinants and some adhesion molecules are engaged
in the regulation of nitric oxide production in vitro by human
monocytes stimulated with colon carcinoma cells. Clin Immunol
Immunopathol 77: 380-384, 1995.
34 Mytar B, Siedlar M, Woloszyn M, Colizzi V and Zembala M:
Cross-talk between human monocytes and cancer cells during
reactive oxygen intermediates generation: the essential role of
hyaluronan. Int J Cancer 94: 727-732, 2001.
35 Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar
M, Ruggiero I, Wieckiewicz J and Zembala M: Tumor cell-
induced deactivation of human monocytes. J Leukoc Biol 74:
1094-1101, 2003.
36 Grage-Griebienow E, Flad HD, Ernst M, Bzowska M,
Skrzeczynska J and Pryjma J: Human MO subsets as defined by
expression of CD64 and CD16 differ in phagocytic activity and
generation of oxygen intermediates. Immunobiology 202: 42-50,
2000.
37 Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich
B, Mack M, Frankenberger M, Weber KS and Ziegler-Heitbrock
HW: Differential chemokine receptor expression and function in
human subpopulations. J Leukoc Biol 67: 699-704, 2000.
38 Zembala M, Siedlar M, Ruggiero I, Wieckiewicz J, Mytar B,
Mattei M and Colizzi V: The MHC class II and CD44 molecules
are involved in the induction of tumour necrosis factor (TNF)
gene expression by human monocytes stimulated with tumour
cells. Int J Cancer 56: 269-274, 1994.
Received May 31, 2010
Revised June 21, 2010
Accepted June 25, 2010
Baj-Krzyworzeka et al: TMV and Monocyte Subsets
3519
